THE PROBLEM
Kidney cancer receives federal funding through its research program – the Kidney Cancer Research Program (KCRP) – with its own funding allocation through the Congressionally Directed Medical Research Programs (CDMRPs). While growing this allocation is important, this is only one way that federal advocacy can play a role in benefiting kidney cancer. The kidney cancer community needs a leader in additional efforts outside of the KCRP.

THE SOLUTION
The KCA will advocate for increased funding and the removal of systemic roadblocks to alleviate patient burden, in terms of access to quality care, fair drug pricing, and insurance coverage.